Compare · DXCM vs OSRH
DXCM vs OSRH
Side-by-side comparison of DexCom Inc. (DXCM) and OSR Holdings Inc. (OSRH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and OSRH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 8223.6x OSRH ($4.1M).
- Over the past year, DXCM is up 17.1% and OSRH is down 88.0% - DXCM leads by 105.0 points.
- OSRH has been more active in the news (11 items in the past 4 weeks vs 9 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 0 for OSRH).
- Company
- DexCom Inc.
- OSR Holdings Inc.
- Price
- $89.16-2.09%
- $0.12-53.17%
- Market cap
- $33.65B
- $4.1M
- 1M return
- +21.53%
- -73.24%
- 1Y return
- +17.08%
- -87.96%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2023
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest OSRH
- OSR Holdings Inc. filed SEC Form 8-K: Other Events
- OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
- OSR Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
- OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
- SEC Form 10-Q filed by OSR Holdings Inc.
- OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
- SEC Form 8-K filed by OSR Holdings Inc.
- OSR Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program